Skip to main content
Top
Published in: Current Infectious Disease Reports 2/2010

01-03-2010

Recent Advances in the Understanding and Management of Kawasaki Disease

Authors: Anne H. Rowley, Stanford T. Shulman

Published in: Current Infectious Disease Reports | Issue 2/2010

Login to get access

Abstract

Kawasaki disease (KD) is an acute systemic inflammatory illness of childhood that can result in coronary artery aneurysms, myocardial infarction, and sudden death. Clinical and epidemiologic data point to an unknown infectious agent as the cause. We discovered that an oligoclonal IgA immune response is present in arterial tissue in acute KD. Synthetic versions of prevalent IgA antibodies in the KD arterial wall identify cytoplasmic inclusion bodies in acute KD ciliated bronchial epithelium and other inflamed KD tissues. Light and electron microscopic studies show that the inclusion bodies are consistent with aggregates of viral protein and RNA, and are likely formed by the KD etiologic agent. KD susceptibility is likely to be polygenic. Treatment of gammaglobulin nonresponders usually consists of additional intravenous immunoglobulin, methylprednisolone, and/or infliximab. Additional data regarding KD pathogenesis are urgently needed to provide other targets for therapy for those patients at highest risk of developing coronary artery abnormalities.
Literature
1.
go back to reference Newburger JW, Takahashi M, Gerber MA, et al.: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114:1708–1733.CrossRefPubMed Newburger JW, Takahashi M, Gerber MA, et al.: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114:1708–1733.CrossRefPubMed
2.
go back to reference Rowley AH, Baker SC, Shulman ST, et al.: Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J Infect Dis 2004, 190:856–865.CrossRefPubMed Rowley AH, Baker SC, Shulman ST, et al.: Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J Infect Dis 2004, 190:856–865.CrossRefPubMed
3.
4.
go back to reference Newburger JW, Takahashi M, Beiser AS, et al.: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633–1639.PubMed Newburger JW, Takahashi M, Beiser AS, et al.: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633–1639.PubMed
5.
6.
go back to reference Kawasaki T: [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967, 16:178–222.PubMed Kawasaki T: [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967, 16:178–222.PubMed
7.
go back to reference Landing BH, Larson EJ: Are infantile periarteritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from North America with patients from Hawaii and Japan. Pediatrics 1977, 59:651–662.PubMed Landing BH, Larson EJ: Are infantile periarteritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from North America with patients from Hawaii and Japan. Pediatrics 1977, 59:651–662.PubMed
8.
go back to reference Amano S, Hazama F, Hamashima Y: Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ J 1979, 43:633–643.PubMed Amano S, Hazama F, Hamashima Y: Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ J 1979, 43:633–643.PubMed
9.
go back to reference Amano S, Hazama F, Hamashima Y: Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979, 43:741–748.PubMed Amano S, Hazama F, Hamashima Y: Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979, 43:741–748.PubMed
10.
go back to reference Amano S, Hazama F, Kubagawa H, et al.: General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations. Acta Pathol Jpn 1980, 30:681–694.PubMed Amano S, Hazama F, Kubagawa H, et al.: General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations. Acta Pathol Jpn 1980, 30:681–694.PubMed
11.
go back to reference Fatica NS, Ichida F, Engle MA, Lesser ML: Rug shampoo and Kawasaki disease. Pediatrics 1989, 84:231–234.PubMed Fatica NS, Ichida F, Engle MA, Lesser ML: Rug shampoo and Kawasaki disease. Pediatrics 1989, 84:231–234.PubMed
12.
13.
go back to reference Nash MC, Shah V, Reader JA, Dillon MJ: Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Br J Rheumatol 1995, 34:882–887.CrossRefPubMed Nash MC, Shah V, Reader JA, Dillon MJ: Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Br J Rheumatol 1995, 34:882–887.CrossRefPubMed
14.
go back to reference Yanagawa H, Nakamura Y, Kawasaki T, Shigematsu I: Nationwide epidemic of Kawasaki disease in Japan during winter of 1985–86. Lancet 1986, 2:1138–1139.CrossRefPubMed Yanagawa H, Nakamura Y, Kawasaki T, Shigematsu I: Nationwide epidemic of Kawasaki disease in Japan during winter of 1985–86. Lancet 1986, 2:1138–1139.CrossRefPubMed
15.
go back to reference Rowley AH, Shulman ST, Spike BT, et al.: Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001, 166:1334–1343.PubMed Rowley AH, Shulman ST, Spike BT, et al.: Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001, 166:1334–1343.PubMed
16.
go back to reference Lee HH, Shin JS, Kim DS: Immunoglobulin V(H) chain gene analysis of peripheral blood IgM-producing B cells in patients with Kawasaki disease. Yonsei Med J 2009, 50:493–504.CrossRefPubMed Lee HH, Shin JS, Kim DS: Immunoglobulin V(H) chain gene analysis of peripheral blood IgM-producing B cells in patients with Kawasaki disease. Yonsei Med J 2009, 50:493–504.CrossRefPubMed
17.
go back to reference Choi IH, Chwae YJ, Shim WS, et al.: Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol 1997, 159:481–486.PubMed Choi IH, Chwae YJ, Shim WS, et al.: Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol 1997, 159:481–486.PubMed
18.
go back to reference Suenaga T, Suzuki H, Shibuta S, et al.: Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr 2009, 155:266–270.CrossRefPubMed Suenaga T, Suzuki H, Shibuta S, et al.: Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr 2009, 155:266–270.CrossRefPubMed
19.
go back to reference •• Rowley AH, Baker SC, Orenstein JM, Shulman ST: Searching for the cause of Kawasaki disease—cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008, 6:394–401. This article reviews etiologic, pathologic, and immunologic studies in KD, including the discovery that viral-like cytoplasmic inclusion bodies are present in KD tissues, and proposes a model of KD pathogenesis. •• Rowley AH, Baker SC, Orenstein JM, Shulman ST: Searching for the cause of Kawasaki disease—cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008, 6:394–401. This article reviews etiologic, pathologic, and immunologic studies in KD, including the discovery that viral-like cytoplasmic inclusion bodies are present in KD tissues, and proposes a model of KD pathogenesis.
20.
go back to reference Rowley AH, Eckerley CA, Jack HM, et al.: IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997, 159:5946–5955.PubMed Rowley AH, Eckerley CA, Jack HM, et al.: IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997, 159:5946–5955.PubMed
21.
go back to reference Rowley AH, Shulman ST, Mask CA, et al.: IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000, 182:1183–1191.CrossRefPubMed Rowley AH, Shulman ST, Mask CA, et al.: IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000, 182:1183–1191.CrossRefPubMed
22.
go back to reference Brown TJ, Crawford SE, Cornwall ML, et al.: CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001, 184:940–943.CrossRefPubMed Brown TJ, Crawford SE, Cornwall ML, et al.: CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001, 184:940–943.CrossRefPubMed
23.
go back to reference Rowley AH, Shulman ST, Garcia FL, et al.: Cloning the arterial IgA antibody response during acute Kawasaki disease. J Immunol 2005, 175:8386–8391.PubMed Rowley AH, Shulman ST, Garcia FL, et al.: Cloning the arterial IgA antibody response during acute Kawasaki disease. J Immunol 2005, 175:8386–8391.PubMed
24.
go back to reference Rowley AH, Baker SC, Shulman ST, et al.: Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis 2005, 192:1757–1766.CrossRefPubMed Rowley AH, Baker SC, Shulman ST, et al.: Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis 2005, 192:1757–1766.CrossRefPubMed
25.
go back to reference • Rowley AH, Baker SC, Shulman ST, et al.: RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE 2008, 3:e1582. This article describes a study demonstrating the presence of RNA-containing cytoplasmic inclusion bodies in 85% of acute and late-stage KD fatalities, and in 25% of adult controls, consistent with the hypothesis that KD is the result of infection with a previously unidentified, ubiquitous, persistent RNA virus. • Rowley AH, Baker SC, Shulman ST, et al.: RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE 2008, 3:e1582. This article describes a study demonstrating the presence of RNA-containing cytoplasmic inclusion bodies in 85% of acute and late-stage KD fatalities, and in 25% of adult controls, consistent with the hypothesis that KD is the result of infection with a previously unidentified, ubiquitous, persistent RNA virus.
26.
go back to reference Holman RC, Curns AT, Belay ED, et al.: Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003, 112(3 Pt 1):495–501.CrossRefPubMed Holman RC, Curns AT, Belay ED, et al.: Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003, 112(3 Pt 1):495–501.CrossRefPubMed
27.
go back to reference Nakamura Y, Yashiro M, Uehara R, et al.: Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005–2006. J Epidemiol 2008, 18:167–172.CrossRefPubMed Nakamura Y, Yashiro M, Uehara R, et al.: Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005–2006. J Epidemiol 2008, 18:167–172.CrossRefPubMed
28.
go back to reference Onouchi Y, Tamari M, Takahashi A, et al.: A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 2007, 52:179–190.CrossRefPubMed Onouchi Y, Tamari M, Takahashi A, et al.: A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 2007, 52:179–190.CrossRefPubMed
29.
go back to reference • Onouchi Y, Gunji T, Burns JC, et al.: ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008, 40:35–42. This study shows an association between a polymorphism of ITPKC that results in inefficient downregulation of T-lymphocyte activation and susceptibility both to KD and to the development of coronary artery abnormalities. • Onouchi Y, Gunji T, Burns JC, et al.: ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008, 40:35–42. This study shows an association between a polymorphism of ITPKC that results in inefficient downregulation of T-lymphocyte activation and susceptibility both to KD and to the development of coronary artery abnormalities.
30.
go back to reference •• Onouchi Y: Molecular genetics of Kawasaki disease. Pediatr Res 2009, 65(5 Pt 2):46R–54R. This article is an outstanding review of the history of genetics studies in KD, and a discussion of future research in this area. •• Onouchi Y: Molecular genetics of Kawasaki disease. Pediatr Res 2009, 65(5 Pt 2):46R–54R. This article is an outstanding review of the history of genetics studies in KD, and a discussion of future research in this area.
31.
go back to reference Burgner D, Davila S, Breunis WB, et al.: A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009, 5:e1000319.CrossRefPubMed Burgner D, Davila S, Breunis WB, et al.: A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009, 5:e1000319.CrossRefPubMed
32.
go back to reference Newburger JW, Takahashi M, Burns JC, et al.: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986, 315:341–347.PubMedCrossRef Newburger JW, Takahashi M, Burns JC, et al.: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986, 315:341–347.PubMedCrossRef
33.
go back to reference •• Newburger JW, Sleeper LA, McCrindle BW, et al.: Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007, 356:663–675. This study demonstrated a lack of efficacy of intravenous methylprednisolone with IVIG and aspirin as compared with IVIG and aspirin alone as primary therapy of KD. •• Newburger JW, Sleeper LA, McCrindle BW, et al.: Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007, 356:663–675. This study demonstrated a lack of efficacy of intravenous methylprednisolone with IVIG and aspirin as compared with IVIG and aspirin alone as primary therapy of KD.
34.
go back to reference Asai T: Evaluation method for the degree of seriousness in Kawasaki disease. Acta Paediatr Jpn 1983, 25:170–175. Asai T: Evaluation method for the degree of seriousness in Kawasaki disease. Acta Paediatr Jpn 1983, 25:170–175.
35.
go back to reference Sundel RP, Burns JC, Baker A, et al.: Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993, 123:657–659.CrossRefPubMed Sundel RP, Burns JC, Baker A, et al.: Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993, 123:657–659.CrossRefPubMed
36.
go back to reference Wallace CA, French JW, Kahn SJ, Sherry DD: Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000, 105:E78.CrossRefPubMed Wallace CA, French JW, Kahn SJ, Sherry DD: Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000, 105:E78.CrossRefPubMed
37.
go back to reference Kusakawa S, Tatara K: Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res 1987, 250:401–413.PubMed Kusakawa S, Tatara K: Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res 1987, 250:401–413.PubMed
38.
go back to reference Furukawa T, Kishiro M, Akimoto K, et al.: Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008, 93:142–146.CrossRefPubMed Furukawa T, Kishiro M, Akimoto K, et al.: Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008, 93:142–146.CrossRefPubMed
39.
go back to reference Lang BA, Yeung RS, Oen KG, et al.: Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006, 33:803–809.PubMed Lang BA, Yeung RS, Oen KG, et al.: Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006, 33:803–809.PubMed
40.
go back to reference Wright DA, Newburger JW, Baker A, Sundel RP: Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128:146–149.CrossRefPubMed Wright DA, Newburger JW, Baker A, Sundel RP: Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128:146–149.CrossRefPubMed
41.
go back to reference Hashino K, Ishii M, Iemura M, et al.: Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43:211–217.CrossRefPubMed Hashino K, Ishii M, Iemura M, et al.: Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43:211–217.CrossRefPubMed
42.
go back to reference Maury CP, Salo E, Pelkonen P: Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. J Lab Clin Med 1989, 113:651–654.PubMed Maury CP, Salo E, Pelkonen P: Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. J Lab Clin Med 1989, 113:651–654.PubMed
43.
go back to reference Matsubara T, Furukawa S, Yabuta K: Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990, 56:29–36.CrossRefPubMed Matsubara T, Furukawa S, Yabuta K: Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990, 56:29–36.CrossRefPubMed
44.
go back to reference Burns JC, Mason WH, Hauger SB, et al.: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146:662–667.CrossRefPubMed Burns JC, Mason WH, Hauger SB, et al.: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146:662–667.CrossRefPubMed
45.
go back to reference Burns JC, Best BM, Mejias A, et al.: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833–838.CrossRefPubMed Burns JC, Best BM, Mejias A, et al.: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833–838.CrossRefPubMed
46.
go back to reference Son MB, Gauvreau K, Ma L, et al.: Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009, 124:1–8.CrossRefPubMed Son MB, Gauvreau K, Ma L, et al.: Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009, 124:1–8.CrossRefPubMed
47.
go back to reference Lee TJ, Kim KH, Chun JK, Kim DS: Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008, 49:714–718.CrossRefPubMed Lee TJ, Kim KH, Chun JK, Kim DS: Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008, 49:714–718.CrossRefPubMed
48.
go back to reference Mori M, Imagawa T, Katakura S, et al.: Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004, 14:43–47.CrossRefPubMed Mori M, Imagawa T, Katakura S, et al.: Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004, 14:43–47.CrossRefPubMed
49.
go back to reference Terai M, Kohno Y, Niwa K, et al.: Imbalance among T-cell subsets in patients with coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 1987, 60:555–559.CrossRefPubMed Terai M, Kohno Y, Niwa K, et al.: Imbalance among T-cell subsets in patients with coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 1987, 60:555–559.CrossRefPubMed
50.
go back to reference Terai M, Yasukawa K, Honda T, et al.: Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002, 21:777–781.CrossRefPubMed Terai M, Yasukawa K, Honda T, et al.: Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002, 21:777–781.CrossRefPubMed
Metadata
Title
Recent Advances in the Understanding and Management of Kawasaki Disease
Authors
Anne H. Rowley
Stanford T. Shulman
Publication date
01-03-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 2/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0091-6

Other articles of this Issue 2/2010

Current Infectious Disease Reports 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.